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the identification of transcriptional enhancers in the human genome is a prime goal in biology. enhancers are typically predicted via chromatin marks, yet their function is primarily assessed with plasmid-based reporter assays. here, we show that such assays are rendered unreliable by two previously reported phenomena relating to plasmid transfection into human cells: (i) the bacterial plasmid origin of replication (ori) functions as a conflicting core promoter and (ii) a type i interferon (iFn-i) response is activated. these cause confounding false positives and negatives in luciferase assays and stArr-seq screens. We overcome both problems by employing the ori as core promoter and by inhibiting two iFni-inducing kinases, enabling genome-wide stArr-seq screens in human cells. in hela-s3 cells, we uncover strong enhancers, iFn-i-induced enhancers, and enhancers endogenously silenced at the chromatin level. our findings apply to all episomal enhancer activity assays in mammalian cells and are key to the characterization of human enhancers.
While promoters are located at the 5′ end of genes and initiate transcription locally, enhancers can activate transcription from distal core promoters 1 . Enhancer activity assays typically place candidate DNA fragments downstream of a reporter gene or a barcode sequence, which ensures the assessment of enhancer rather than promoter activity. Importantly, however, in human cells reporter transcripts from the widely used pGL3/4 system (for massively parallel reporter assays (MPRAs) based on this system see Supplementary Table 1 and Santiago-Algarra et al. 2 ) initiate predominantly in the bacterial plasmid ORI rather than the minimal core promoter 3 (fly cells do not seem to be affected 4 ). While the function of the ORI as a core promoter is not unexpected, given the presence of core promoter elements 3 (Supplementary Fig. 1a ) and the ORI's propensity to remain nucleosome free 5 , it will likely impact enhancer activity measurements; the undefined 5′ UTR, differences in reporter transcript stability, or transcriptional interference between the two core promoters can affect assays that measure reporter abundance at the protein or RNA level, as all sequencing-based MPRAs, including, STARR-seq do 1,2 . resolving systematic errors in widely used enhancer activity assays in human cells results stArr-seq reporter transcripts initiate in the ori rather than in core promoters Similarly to single-candidate luciferase assays, STARR-seq tests candidates downstream of a core promoter yet is as comprehensive as comprehensive libraries with hundreds of millions of fragments 6 . To assess where reporter transcription initiates in STARR-seq, we mapped the initiation sites of reporter transcripts 7 in HeLa-S3 cells using STARR-seq libraries with two frequently used synthetic core promoters, two endogenous core promoters, and one non-core-promoter control. In line with the findings for luciferase reporters 3 , most reporter transcripts (≥77.5%) initiated within the ORI, and almost no initiation occurred within the core promoters (≤1.5%; Fig. 1a ) or other backbone positions (Supplementary Fig. 1b ). Even SCP1 (ref. 8) , which was the only exception, as it gave rise to 27.0% of all reporter transcripts presumably on account of its high(er) basal activity, was less efficient than the ORI (59.1%).
ori-derived stArr-seq reporter transcripts identify active enhancers
To test whether ORI-initiation affected the enhancer activity profiles, we processed the same samples using the STARR-seq protocol 6 (Supplementary Fig. 1c ). All five setups show similar profiles that identify active enhancers, despite considerable background. When we separated reporters that initiated within the SCP1 or the ORI, we obtained highly similar enhancer-activity profiles (Supplementary Fig. 1d ), which suggested that the ORI functions as a highly inducible core promoter that responds to human enhancers. the ori is an optimal core promoter for stArr-seq and luciferase assays To capitalize on the efficiency of the ORI as a core promoter, we cloned STARR-seq libraries in which the ORI is used as core promoter placed immediately upstream of reporter gene and candidate library. This should provide maximal enhancer-mediated activation, avoid the presence of two potentially conflicting core promoters, and prevent transcription and splicing across the ~2-kb intervening plasmid sequence 3 . Indeed, STARR-seq in HeLa-S3 cells with these constructs showed improved signal over background for putative enhancers predicted based on chromatin features (Fig. 1b,c and Supplementary Fig. 1e ) and for luciferase-validated enhancers (Supplementary Fig. 1f ).
Using the ORI as a core promoter also improved STARR-seq signals in the colorectal cancer cell line HCT-116 (Fig. 1b,c and Supplementary Fig. 1g) .
Importantly, these improvements also applied to single-candidate luciferase assays: reporter transcription was induced up to tenfold more strongly by cellular and up to 40-fold more strongly by viral enhancers in the ORI-based setup compared to two core-promoter-based setups (Fig. 1d) . Together, these results suggest that employing the ORI as core promoter improves the signal of single-candidate luciferase assays and MPRAs such as STARR-seq and should be applicable to barcode-based MPRAs that rely on different cloning strategies ( Supplementary Fig. 1h ,i; see Supplementary Fig. 1j for alternative setups that block ORIderived transcripts).
dnA transfection into human cells mounts an interferon response
As cytoplasmic DNA is prevalent during plasmid DNA transfection 9 , we hypothesized that enhancer activity assays in human cells might suffer from an innate immune response-most mammalian cell types and many immortalized cell lines sense cytoplasmic DNA and induce IFN-I expression via cGAS, STING, TBK1, and IRF transcription factors 10, 11 . This substantially changes gene expression, which suggests that the corresponding enhancer activities are also altered.
For example, expression of the interferon pathway genes cGAS, STING, TBK1, and PKR groups 19 ENCODE cell lines into three main clusters ( Supplementary Fig. 2a ); four have low levels of STING mRNA, and four-including HCT-116-have low cGAS mRNA levels, which suggests that their ability to induce interferon-stimulated genes (ISGs) in response to cytosolic DNA might be compromised. This has indeed been observed for five of the eight cell lines ( Supplementary Fig. 2a and references therein), and we confirm the lack of ISG induction after transfection of a STARR-seq library by electroporation for HCT-116, K562, and SK-N-SH cells (Supplementary Fig. 2b) .
In contrast, the majority of all cell lines (10 out of 18), including the widely used HeLa-S3 cells, show high expression of interferon pathway genes including cGAS and STING. Induction of ISGs is known for three of these ( Supplementary  Fig. 2a and references therein), and we confirm ISG induction for HeLa-S3 and GM12878 cells as well as for two additional widely used cell lines (U937 and THP1; Supplementary  Fig. 2c ). ISG induction was not specific to STARR-seq-library electroporation, but also occurred for luciferase reporter plasmids, pBluescript (see also Bridge et al. 12 ), a plasmid without any CpG dinucleotides ( Supplementary Fig. 2d ), and for chemical transfection (Supplementary Fig. 2e ). These findings, together with similar reports in the literature (see references in Supplementary Fig. 2a ), demonstrate that IFN-I-related gene induction by plasmid transfection is a widespread phenomenon that affects many widely used cell lines. enhancer activity assays in hela-s3 cells are dominated by iFn-i signaling The IFN-I-related gene induction suggests that the corresponding enhancer and promoter activities are also changed. Indeed, in HeLa-S3 cells, putative enhancers proximal to canonical ISGs were highly active in luciferase assays ( Fig. 2a) , and a genomewide STARR-seq screen was dominated by enhancers related to IFN-I signaling; genes proximal to the top 1,000 enhancers were strongly enriched for gene ontology (GO) terms relating to cellular immunity and IFN-I signaling (Fig. 2b,c) , similar to a focused STARR-seq screen testing ~21,000 promoter regions for enhancer activity 13 . Additionally, disease-ontology analyses pointed toward viral infection rather than cervical cancer as one would expect for HeLa cells (Supplementary Fig. 3a) , in which genes related to IFN-I signaling are not particularly highly expressed 14 . Together with the fact that ISG induction is independent of plasmid type and delivery ( Supplementary Fig. 2d,e ), these results indicate that all plasmid-based luciferase assays and MPRAs should suffer from plasmid-induced IFN-I signaling. Indeed, we find luciferase and STARR-seq assays to be affected ( Fig. 2a-c) ; and several studies using synthetic, barcode-based MPRAs or libraries enriched for selected candidates reported high activities of IFN-I-related enhancers and/or enrichments of IFN-I-related transcription factor binding sites indicative of IFN-I signaling 13, 15, 16 .
tBK1/iKKε and PKr inhibition prevents dominant falsepositive iFn-1-related enhancer signals
Cytoplasmic DNA leads to IFN-I induction via the key signaling kinases TANK-binding-kinase-1 (TBK1) and IκB-kinase-ε (IKKε), which activate IRF3 (ref. 17) . Similarly, double-stranded RNA (dsRNA) can arise at plasmids and activate protein kinase R (PKR), which affects transgene expression [18] [19] [20] . The inhibition of these kinases (or other pathway components) should ameliorate the changes of gene expression and enhancer activities described above. Indeed, treating HeLa-S3 cells during plasmid transfection with the TBK1/IKK inhibitor BX-795 (ref. 21 ) and the PKR inhibitor C16 (ref. 22 ) prevents the strong induction of ISGs observed after plasmid transfection in HeLa-S3 cells ( Fig. 2d) .
Moreover, enhancers proximal to canonical ISGs that were previously among the strongest STARR-seq signals genome wide were only detected at background levels in an inhibitor-treated STARR-seq screen (Fig. 2b) . Genes near the top 1,000 peaks were no longer enriched in interferon-signaling-related GO categories ( Fig. 2c , right panel; Supplementary Fig. 3b ), indicating that TBK1/IKK/PKR inhibition removes these dominant falsepositive signals. Consistently, STARR-seq peaks that lost activity upon TBK1/IKK/PKR inhibition (≥5-fold downregulation, P value < 0.001) were next to interferon-signaling-related genes ( Supplementary Fig. 3c,d ) and were highly enriched in motifs of transcription factors involved in ISG induction ( Fig. 2e) . Finally, luciferase assays confirmed that enhancers proximal to ISGs showed strongly reduced activity in cells treated with TBK1/IKK/PKR inhibitors during plasmid transfection ( Fig. 2f ). This demonstrates that plasmid-induced IFN-Irelated false-positive enhancer activities can be prevented by TBK1/IKK/PKR inhibition. The importance of TBK1/IKK/PKR inhibition for accurate enhancer activity assessment is particularly evident when analyzing disease ontology terms near the top STARR-seq peaks 23 ; without inhibitors, the top terms relate to viral infection (likely on account of strong interferon signaling), while inhibitor treatment reveals terms relating to female reproductive cancer, consistent with HeLa-S3 cell biology ( Supplementary Fig. 3a) .
A genome-wide set of iFn-i-related enhancers
The comparison of the genome-wide STARR-seq screens with and without TBK1/IKK/PKR inhibitors also defines a genome-wide set of IFN-I-related enhancers and their respective induction strengths, some of which were more than 100fold ( Supplementary Fig. 3e and Supplementary Table 2 ).
Interestingly, many of these predominantly promoter-proximal enhancers were premarked by H3K27ac in unperturbed HeLa-S3 cells ( Supplementary Fig. 3e ), which might be a general feature of rapidly inducible enhancers 24 . This genome-wide set of IFN-Irelated enhancers ( Supplementary Table 2 ) is a valuable resource for the study of IFN-I-mediated transcriptional regulation.
tBK1/iKK/PKr inhibition prevents false-negative signals and improves signal over background
Of the enhancers we tested individually in luciferase assays, the activity of two endogenous HeLa-S3 cell enhancers and one viral Figure 1 | The ORI is an optimal core-promoter for STARR-seq and luciferase assays. (a) Reporter-transcript initiation (in reads per million (RPM)) on STARR-seq plasmids as measured by STAP-seq 7 for setups with two synthetic core promoters (mCP, SCP1) and two endogenous core promoters (TFF2, SULT1C2) versus a negative control (ctrl., OCT4 3′ UTR). Red vertical lines indicate transcription initiation sites with the respective initiation frequencies according to STAP-seq. The percentages indicate the fraction of all initiation events in either the ORI or the respective core promoter. End., endogenous; CPs, core promoters. enhancer was increased after TBK1/IKK/PKR inhibition ( Fig. 2f ). This suggests that IFN-I-signaling might also repress bona fide enhancers, leading to an underestimation of their activities or false negatives. Indeed, the STARR-seq signal increased substantially in inhibitor-treated HeLa-S3 cells ( Supplementary  Fig. 3f ), but not in HCT-116 cells, which do not induce ISGs after DNA transfection ( Supplementary Fig. 3g ). The signal increase is therefore specific, and inhibitor treatment should not otherwise impact enhancer activities.
Overall, our results indicate that previous approaches may have substantially underestimated enhancer activities ( Fig. 1b-d) , potentially missing up to 75% of all enhancers ( Supplementary  Fig. 3h,i) ; and that enhancer-activity screens in cells with intact innate-immune signaling are dominated by false positives (Fig. 2c) , which grossly alters the cells' enhancer landscapes ( Supplementary Fig. 3a,e ).
stArr-seq enhancers are mostly intergenic or intronic and are enriched in enhancer-associated chromatin states
The genome-wide STARR-seq screen using the new screening setup and TBK1/IKK/PKR inhibitors yielded 9,613 peaks, of which 2,508 have a corrected enrichment of ≥10-fold and 209 of ≥50-fold. The enhancer activity profiles are highly similar between replicates (PCC = 0.98). Almost half of all peaks are in intergenic regions (48.3%), and 43.2% are within introns ( Supplementary  Fig. 4a ). The peaks significantly overlap with regions that exhibit enhancer-or promoter-associated chromatin states according to chromHMM 25 ; all 9,613 STARR-seq peaks are enriched 20.5-fold in the strong enhancer state Enh, 6.7-fold in the weak enhancer state EnhW, and 6.6-fold in the active promoter state TSS, compared to these states' genomic abundance (Fig. 3a) . The enrichment for the Enh state was 40.3-fold for the top 500 peaks and still ~9-fold for the weakest peaks, suggesting that even subthreshold 
with inh./without inh.
Enh.: peaks might be functional in vivo, albeit with weak effects on transcription ( Supplementary Fig. 4b and Supplementary Table 2 ). Furthermore, peaks that are accessible in HeLa-S3 cells according to ENCODE DNase-seq (42.3%, Supplementary Table 3 ) align precisely with characteristic enhancer features ( Fig. 3b) .
stArr-seq-negative enhancer candidates are associated with rnA polymerase iii transcription
ChromHMM Enh regions that do not show activity in enhancer activity assays such as STARR-seq would generally be considered nonfunctional 1 ; yet 1,323 such regions (8.9%) are bound by RNA polymerase III (Pol III) or its general transcription factor 3C, yielding a strong enrichment according to i-cisTarget 26 (Fig. 3c) . Pol III typically transcribes noncoding genes from promoters that are independent of enhancer-like upstream regions 27 yet can bear chromatin marks reminiscent of Pol II enhancers 28 . The transcription factors JUN, MAX, MYC, or FOS were enriched to similar extents in ChromHMM regions with or without STARR-seq signals (EP300 and TCF7L2 were slightly more enriched in STARR-seq-positive regions, Fig. 3c ).
Open STARR-seq enhancers that do not overlap chromHMM Enh regions show similar enrichments for different TFs and an even slightly higher enrichment for the TFs JUN and JUND and for EP300, as expected for bona-fide enhancers ( Supplementary  Fig. 4c ). Interestingly, TSS-distal and TSS-proximal enhancers differed in motif content ( Supplementary Fig. 4d ), transcription factor binding ( Supplementary Fig. 4e ), and histone modifications ( Supplementary Fig. 4f ), suggesting that they might be regulated differently.
A substantial fraction of enhancers is silenced at the chromatin level
One of the advantages of ectopic assays such as STARR-seq is their ability to assess the enhancer activities of DNA sequences that are able to strongly activate transcription yet are silenced endogenously at the chromatin level 6 . While a large fraction of the STARR-seq enhancers were accessible in their endogenous genomic locations according to ENCODE DNase-seq (56.2% of the top 500 and 42.3% of all 9,613 enhancers; Supplementary  Table 3 ), 57.7% of STARR-seq enhancers were not accessible (i.e., closed) and thus likely actively silenced (Fig. 4a) . This included DNA sequences that can function as very strong enhancers in HeLa-S3 cells, such as peak 89 in the CWC27 locus or peak 384 in the HMX1 locus ( Fig. 4b) . 
closed stArr-seq enhancers are open in other cell types and marked by h3K27me3
Interestingly, the closed enhancers are strongly enriched in DNase-I-hypersensitive regions of five ENCODE cell lines according to i-cisTarget 26 (e.g., HMVEC or HCFaa cells; Fig. 4c ). Together, DNase-I hypersensitivity in these five non-HeLa cell types accounts for 39.3% of the closed HeLa-S3 enhancers ( Fig. 4a ; see Supplementary Table 3) , and almost all HeLa-S3 STARR-seq enhancers appear accessible in at least 1 of 13 ENCODE cell lines ( Supplementary Fig. 5a ; though an increasing fraction cannot be discerned from chance expectation given the increasing number of DNase-I-hypersensitive sites).
Closed HeLa-S3 enhancers were enriched for H3K27me3 ( Fig. 4d) , consistent with Polycomb-mediated repression 29 , and marked by H3K4me1 (albeit less than accessible enhancers; Fig. 4e ). This suggests that they might be recognized as enhancers (as in flies 6 ) and is consistent with previous reports that H3K4me1 labels enhancers independently of their activity [30] [31] [32] . (LINEs) were depleted overall within closed peaks, elements from three families of endogenous retroviruses (ERVs) were highly enriched and overlapped with 13.0% of all closed peaks (Supplementary Fig. 5b) . These peaks exhibited a significantly higher signal of H3K9me3 than other regions ( Fig. 4f) , suggesting that they constitute active regulatory regions that are repressed at the chromatin level 34 .
As expected for bona fide enhancers, ERVs that are active according to STARR-seq are enriched in binding motifs of various transcription factors (e.g., FOS and JUN) compared to inactive ERVs (Fig. 5a) . Consistently, active ERVs were enriched for ChIP-seq-determined binding of several TFs according to i-cisTarget (e.g., FOS and JUN; Fig. 5b ), suggesting that such elements can escape silencing and/or might be co-opted for transcriptional regulation 35, 36 .
The only enrichment specific to inactive ERV elements was for an ENCODE data set that assessed STAT1 binding after IFNγ treatment ( Supplementary Table 3 ). This suggests that some ERVs are activated by IFNγ, either because they evolved interferon responsiveness or because such elements were co-opted as cellular interferon-responsive enhancers 35 . Indeed, inactive ERVs with STAT transcription factor binding motifs were less enriched for the repressive histone mark H3K9me3 compared to both active elements or inactive elements without STAT binding motifs (Fig. 5c) . Additionally, ERVs with STAT motifs are induced during interferon signaling; i.e., they appear more active in STARR-seq screens without inhibitor treatment (Fig. 5d) .
discussion
We show that the core-promoter function of a bacterial ORI and the IFN-I response triggered by cytoplasmic DNA confound enhancer activity assays in mammalian cells. This has important implications for the functional assessment of enhancers by reporter assays, which has become increasingly important and is a major aim of large consortia efforts 37 . Importantly, all published MPRAs are based on the same pGL3/4-derived backbone, and reporter-transcript initiation sites have typically not been mapped. It is therefore possible that the reporter transcripts do not initiate within the core promoters but in the ORI (here and Lemp et al. 3 ) or-particularly for candidates upstream of reporter gene or barcode-within the enhancer candidates (consistent with enhancer RNA (eRNA) transcription in vivo 38 and equivalent to promoter activity assays 39 ) or elsewhere on the plasmid backbone. In addition, all plasmid-based enhancer activity assays should be affected by the IFN-I response, which is independent of plasmid type. Indeed, previous publications assaying ISG enhancer regions with different MPRAs-two with synthetic-barcode-based reporters 15, 16 and three with enriched candidate libraries 13, 40 ,41 -show signs of an active IFN response, such as ISG-enhancer activities and STAT1/2-or IRF-motif enrichments.
Approaches to block ORI-derived transcripts or the use of other low(er)-copy ORIs, ORI-less constructs 42,43 , or reporter delivery using AAV 44 or lentiviral vectors 45,46 should allow for screens with different core promoters. We note that retroviral integration preferences and promoter and/or enhancer elements on viral backbones (e.g., LTRs) should be carefully considered, as they might confound enhancer-activity assays. Lastly, other means to inactivate key signaling factors of innate immune signaling (e.g., knockout cell lines or cGAS inhibition) are alternatives to the inhibitors we propose.
The methods presented here overcome key problems associated with plasmid-based enhancer activity assays, correcting individual candidate luciferase assays and enabling genome-wide STARRseq screens. In HeLa-S3 cells, such screens revealed thousands of human enhancer sequences with activities approaching the strengths of strong viral enhancers. Similar to previous results in flies 6 , many enhancers are silenced in their endogenous loci at the chromatin level. These enhancers are invisible to predictions based on chromatin features, yet they constitute attractive examples to study mechanisms of chromatin-mediated repression. Given these results, we recommend that cellular enhancer function be assessed by combining ectopic enhancer activity assays, such as luciferase assays or STARR-seq, with methods that assess DNA accessibility. The tools and protocols presented here are applicable to all episomal reporter assays in mammalian cells and should become a central component of our efforts to identify all gene regulatory elements of the human genome and understand how their sequences encode cell type-specific gene expression.
methods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
online methods
The methods section is accompanied by laboratory protocols for STARR-seq library cloning (Supplementary Protocol 1) and screening (Supplementary Protocol 2). We further provide protocols for qPCR testing of IFN-I-response (Supplementary Protocol 3) and qPCR reporter assays (Supplementary Protocol 4) .
Experimental methods. Cell lines. We purchased HeLa-S3, HCT-116, and SK-N-SH cells from ATCC (cat# CCL-2.2, CCL-247, CCL-243, HTB-11) and GM12878 cells from Coriell Institute. K562 were a gift from the Zuber lab (IMP), and THP-1 and U937 cells were a gift from the Decker and Versteeg labs (MPFL). Cells were cultured in DMEM (HeLa-S3, HC-116, SK-N-SH; Gibco; cat# 52100-047) or RMPI-1640 (GM12878, K562, U937, THP1; Gibco; cat# 13018-031) supplemented with 10% heat-inactivated FBS (Sigma; cat# F7524, 15% for GM12878) and 2 mM L-glutamine (Sigma; cat# G7513) at 37 °C in a 5% CO 2 -enriched atmosphere.
Electroporation. Cells were electroporated using the MaxCyte-STX system at a density of 1 × 10 7 cells per 100 µl and 20 µg of DNA using the preset protocols (except for opt-program 4 for GM12878 cells).
Chemical transfection. 8 × 10 5 HeLa-S3 cells were plated 24 h before being transfected with 8.8 µg of STARR-seq library using FuGENE-HD reagent (3.5:1 reagent-to-DNA ratio, Promega; cat# E2312).
Plasmid purification. Plasmids for electroporation were purified with Qiagen Plasmid-Plus kits (cat# 12965, 12991) and resuspended in H 2 O. For endotoxin-free preps, Qiagen EndoFree Plasmid maxi kits were used (cat# 12362).
Inhibitor treatment. We used PKR (C16, Sigma; cat# I9785-5MG) and TBK1/IKK inhibitors (BX-795, Sigma; cat# SML0694-5MG) as recommended in the literature 21, 22 , adding them to the electroporated cells directly after resuspension at a final concentration of 1 µM per inhibitor.
Mapping of STARR-seq transcript initiation sites by STAPseq.
STAP-seq was performed as described 7 . Briefly, 50 µg of DNaseI-treated mRNA from STARR-seq library electroporated cells was treated with 25 µl of CIP (NEB; cat# M0290L) for 1.5 h at 37 °C. The CIP-treated RNA was purified with Qiagen RNeasy MinElute kits (cat# 74204) with RLT buffer supplemented with beta-Mercaptoethanol (Sigma-Aldrich; cat# 63689). The CIP-treated RNA was treated with 0.05 µl Tobacco Alkaline Phosphatase (Epicentre; discontinued) per 1 µg RNA and purified with Agencourt RNAClean XP beads (Beckman Coulter; cat# A66514, beads-to-RNA ratio 1.8). We ligated 10 µM RNA adaptor (STAP_adapter, Supplementary Table 4 ) to the 5′ ends of each 1 µg TAP-treated mRNA using 0.2 µl T4 RNA Ligase 1 (NEB; cat# M0204L) for 16 h at 16 °C. The RNA was purified with Agencourt RNAClean XP beads (beads-to-RNA ratio 1.0).
First-strand cDNA synthesis was performed on the total amount of adaptor-ligated RNA. Per reaction, 2.5-5 µg adaptor-ligated RNA was reverse transcribed with 1 µl of Invitrogen′s Superscript III (50 °C for 60 min, 70 °C for 15 min; cat# 18080085) and a reporter-RNA-specific primer (STAP_GSP, Supplementary Table 4) . Five reactions were pooled, and 1 µl of 10 mg/ml RNaseA was added (37 °C for 1 h) followed by Agencourt AMPureXP DNA bead purification (Beckman-Coulter; cat# A63881, ratio beads/ RT reaction 1.8). We amplified the total amount of reporter cDNA for Illumina sequencing. For focused libraries, we performed two PCR reactions using the KAPA real-time library amplification kit (KAPA Biosystems, cat# KK2702) with STAP_fwd ( Supplementary Table 4 ) forward primer and one of NEBNext Multiplex Oligos for Illumina (NEB; cat# E7335 or E7500) reverse primers. PCR products were purified with AMPureXP DNA beads (ratio beads/PCR 1.25).
STARR-seq. Screening vectors.
All STARR-seq vectors are based on the original human STARR-seq vector 6 with the following changes. The GFP coding sequence is truncated, the synthetic intron is replaced with a chimeric intron (Promega, technical bulletin #TB206), and the core promoter is replaced with a panel of different minimal promoters or the ORI (Supplementary Table 4) .
To enable the use of a core promoter in the presence of the ORI, we generated four vectors containing SCP1 and the following changes (see Supplementary Fig. 1h) : blocking variant 1 contains RBGpA polyA-signal 48 and the bGHpA polyA-signal 49 in the SpeI site. Blocking Variant 2 additionally contains bGHpA in the PciI site. Variant 3 contains the bcl-2 splice acceptor and four SV40 polyA-signals at the SpeI site 49 . Variant 4 additionally contains bGHpA at the PciI site.
Cloning of STARR-seq plasmid libraries. Focused STARR-seq libraries were generated from bacterial artificial chromosome (BAC) DNA (see Supplementary Table 4 , BAC mixes). BAC insert 1 was cloned into STARR-seq vectors that harbor different core promoters. BAC insert 2 was used to clone the libraries for all other screens. The library inserts (1,000-1,500 bp) were generated as previously described 6 with the following changes: we used a 45s extension during the final PCR amplification and 10 instead of 8 PCR reactions (primers in-fusion_fwd and in-fusion_rev, Supplementary Table 4 ). To generate genome-wide STARR-seq libraries, we followed the same protocol with changes: we used 15 µg of size-selected genomic DNA (1,000 bp-1,500 bp) for library insert generation, 30 PCR reactions for library insert amplification, 20 In-Fusion HD reactions for library cloning, and transformation of 25 aliquots of Invitrogen MegaX-DH10B Electrocompetent Cells. The bacteria culture was grown in 24 l of LB-Amp.
STARR-seq screening. For focused BAC screens, we electroporated 8 × 10 7 cells per screen, and for genome-wide STARR-seq libraries we electroporated 8 × 10 8 cells per screen. Genomewide STARR-seq screens in HeLa-S3 cells were done in duplicate (inhibitor screens) or quadruplicate (noninhibitor screens). Screens were performed as previously described 6 , with the following changes: we harvested total RNA 6 h after electroporation, and reverse transcription was performed with primer STARR_GSP (Supplementary Table 4 ) in a total of 10-20 reactions for focused and 40-60 reactions for genome-wide STARR-seq screens.
We purified cDNA using AMPureXP DNA beads (beads-to-cDNA ratio of 1.8) and amplified it using human STARR-seq-specific primers (junction_fwd, junction_rev, Supplementary Table 4 ; 98 °C for 45 s followed by 15 cycles of 98 °C for 15 s, 65 °C for 30 s, 72 °C for 70 s). We also increased the extension to 45 s for the second PCR step (primers PE1.0 as forward primer and MP2.0 or TruSeq IDX primers as reverse primer, Supplementary Table 4 ). We set up 2 reactions for focused and 10 reactions for genomewide screens. PCR products were purified using SPRIselect beads (Becker Coulter; cat# B23318, 0.5 beads-to-PCR ratio).
To sequence the un-transfected STARR-seq plasmid library, twenty PCR reactions with 100 ng STARR-seq library were performed (98 °C for 45s; followed by 6-15 cycles of 98 °C for 15s, 65 °C for 30s, 72 °C for 45s) with the KAPA Hifi Hot Start Ready Mix and NEBNext Multiplex Oligos for Illumina (cat# E7335L).
Next-generation sequencing. Next-generation sequencing was performed at the VBCF NGS Unit on an Illumina HiSeq2500. Genome-wide STARR-seq screens were sequenced as paired-end 50 cycle runs, focused BAC screens for signal-to-noise analysis as single-end 50 cycle runs, using the standard Illumina primer mix. STAP-seq screens were sequenced as paired-end 50 cycle runs with TruSeq RP1 primers as read 1 primer. qPCR based methods. Measuring ISG expression levels. 5 × 10 6 cells were electroporated with a focused STARR-seq library in three independent transfections with mock electroporations as negative controls. 6h after transfection, cells were lysed using Qiashredder columns (Qiagen; cat# 79654) and total RNA was extracted using the RNeasy mini prep kit (Qiagen; cat# 74104), with beta-Mercaptoethanol supplemented RLT buffer. 1 µg of total RNA was treated with recombinant DNaseI (rDNaseI; Ambion, cat# AM1906) for 30 min at 37 °C followed by the removal of rDNa-seI using a DNase inactivation reagent (Ambion; cat.no. AM1906). The DNaseI treated RNA was reverse transcribed using Invitrogen′s Superscript III and Oligo-dT 20 primers (Invitrogen; cat# 18418020) (25° for 5 min, 50 °C for 50 min, 70 °C for 15 min), followed by qPCR on 2 µl diluted (1:5) cDNA using Go Tag SYBR Green qPCR Master Mix (Promega; cat# A6001) in a total volume of 20 µl with 0.5 µM gene-specific qPCR primers (95 °C, 2 min; 95 °C, 3s; 60 °C, 30s; 40 cycles total, see Supplementary Table 4 for primers).
qPCR based reporter assay. 5 × 10 6 HeLa-S3 cells were electroporated with 18 µg of a firefly luciferase reporter plasmid and 2 µg of a Renilla luciferase control plasmid (pRL-CMV, Promega; cat# E2261). After 30 min, C16 and BX795 inhibitors were added to the cells at 1 µM concentration. qPCR to quantify firefly luciferase transcripts normalized to Renilla luciferase transcripts was performed as described above, with the exception that we used Turbo DNase (Ambion; cat# AM1907) for cells transfected with reporter plasmids (see Supplementary Table 4 for primer sequences).
Computational methods. TSS determination of STARR-seq reporter transcripts. All sequenced read pairs were subsampled to 500,000 fragments using reservoir sampling 50 . Mate 1 was mapped to the STARR-seq plasmid backbone using bowtie 51 . The 5′ 8nt random barcode introduced during the RNA adaptor ligation 7 was removed and the following 15nt were mapped uniquely allowing for 3 mismatches (bowtie option -v 3 -m 1-best -strata). The resulting mapping locations were collapsed based on the random 8nt barcode, allowing for molecular counting of all reporter mRNA 5′ ends.
Stratification of STARR-seq signal. To stratify genomic fragments based on their origin within the plasmid (for example, ORI vs. CP), mate 1 was used to define the origin, followed by mate 2 mapping to the human genome (bowtie options -v 3 -m 1-best-strata).
STARR-seq data processing. STARR-seq single-and paired-end sequencing reads were mapped in fasta format to the human genome (hg19), only considering the regular chromosomes 1-22, and X using bowtie version 0.12.9 (bowtie options -v 3 -m 1-best -strata -X 2000) 51 . Genome-wide screens without inhibitors and focused screens for signal-to-noise analysis were mapped as 50-mers. Genome-wide screens with inhibitors were mapped as 36-mers due to poor base calls at the 3′ end of the read. Genome coverage bigwig files were generated using all reads with bedtools genomecov version 2.19.1 (ref. 52 ) and normalized to reads per million (r.p.m.). For both genome-wide STARR-seq and input libraries, reads from biological replicates were combined.
Peak calling. Enriched regions were shortlisted using all reads from the combined STARR-seq replicates versus input as described 6 with a P-value cutoff of 1x10 −5 and an enrichment cutoff ≥ 3 (enrichment over input, where input coverage was evaluated locally at the peak summit or over a fixed input window of 20 kb surrounding the summit, whichever was higher) and peaks were then called with a corrected enrichment ≥4 (correction as in Stark et al. 53 , z = 3). We discarded peaks for which a single fragment accounted for more than 50% of all fragments overlapping with the peak and peaks overlapping ENCODE blacklisted regions. Peaks were annotated as open if they had significant enrichments in DHS data sets (binomial P-value < 0.05). This P-value was calculated over the entire STARR-seq peak using the maximum DHS coverage (r.p.m.) over the median coverage in the input, yielding a FDR of 13.6% when applied to random regions. Peaks were annotated with an Ensembl gene ID based on the transcript TSS nearest to the peak's edges using the R package GenomicRanges (version 1.20.8) and its function distanceToNearest. Gene ID annotations were obtained from Ensembl version 75 IDs 54 .
ChIP-seq coverage. Counts for H3K27me3, H3K4me1, and H3K9me3 were calculated for the groups defined by DHS and enriched TEs using bedtools coverage (options -counts -F 0.1). For plotting, a pseudo-count of 1 was added to counts before log 10 transformation.
Random control regions. We selected 9,613 random control regions from all fragments in the STARR-seq input library with a size distribution of 1000 to 1600bp by reservoir sampling (sample version 1.0.2 https://travis-ci.org/alexpreynolds/sample). To match the peak size, we extended each region by 641bp from the center of the fragment.
Comparison of signal-to-noise. To assess improvements in signal-to-noise we (1) evaluated STARR-seq signal-to-noise ratios on a small set of positive (n = 4) and negative (n = 6) regions according to luciferase assays and (2) defined a high-confidence subset of STARR-seq peaks in focused screens with support for endogenous enhancer activity based on DNase-seq and H3K27 acetylation (data sets from ENCODE, Supplementary Table 3 ). We called peaks as described above (P-value cutoff of 1x10 −4 , enrichment cutoff ≥ 3, corrected enrichment ≥ 4, z = 1.67). A binomial P-value for DHS enrichment was calculated in a 20nt window around the peak summit for the median DHS coverage (r.p.m.) over the median coverage in the input of a window of 250. For H3K27ac the maximum coverage was identified in a 500 nt window around the peak summit. For this local maximum, a binomial P-value for H3K27ac enrichment was calculated as described for DHS. Peaks with an FDR adjusted P-value < 0.05 in both the DHS and H3K27ac were used as predicted positive regions. Background signal was assessed over BAC regions minus positive regions. The average coverage was calculated within each positive peak then averaged across all positive peak regions (merged between screens) and divided by the background to give the final signal-to-noise value. For the signal-over-background scatter plots, we used the average STARR-seq read coverage for each peak and divided it by the background as defined above for bar graphs. Correlations were calculated using the Pearson Correlation Coefficient using R's cor function.
Differential peak analysis. Peak calls for PKR/TBK1/IKK inhibited and noninhibited genome-wide STARR-seq screens were combined and collapsed into one region if peaks overlapped by at least 85%. Differential peaks were called using a hypergeometric test using the maximum count in each peak region for each data set. P-values were adjusted to FDRs using R's p.adjust. Peaks less than 2.5 kb away from a nearest TSS that belongs to the top 3 interferon enriched GO terms (response to type I interferon, type I interferon signaling pathway, and cellular response to type I interferon) were highlighted in the scatter plot.
Nearest TSS gene ontology. GO analysis of nearest TSSs was done using topGO version 2.20.0 (ref. 55 ), which reports a Fisher's exact test p-value. All protein coding genes were provided as a background to topGO using Ensembl version 75 IDs 54 . Enrichments were calculated by dividing the significant number of genes in each term by the number of genes that one would expect by chance reported in the topGO output. topGO results were reported for all terms, and P-values were adjusted to FDRs using R's p.adjust.
Disease ontology. Disease ontology analysis was done using GREAT version 3.0.0 (ref. 23 ) with default settings for the top 500 accessible peaks (P-value < 0.05 for DHS) in genome wide screens with and without inhibitor treatment. Bars represent binomial FDR q-values and are colored by binomial fold enrichment.
Motif analysis. For repeat analysis, the sequence of the entire element was used, for distal vs. proximal STARR-seq peaks and differentially active STARR-seq peaks, we used a 700bp window around the peak summits. For differentially active STARR-seq peaks we only considered windows that were at least 50bp away from any transcript TSS (Ensembl version 75 (ref. 54) ). Motifs were called using MAST from the MEME suite version 4.8.1 (ref. 56) using options -hit_list -mt 0.00001. A motif was only counted once within each peak. Odds ratios and P-values were derived using a one-sided Fisher's exact test for comparisons defined in the text. P-values were adjusted with the Benjamini & Hochberg method (FDR) in R.
ChromHMM enrichments. The ChromHMM segmentations were obtained from UCSC 25 . The peak regions were overlapped with these segmentations using bedtools intersect version 2.19.1. The sum of lengths of overlaps for each annotation term was divided over the total length of all terms for either all peaks or all ranked regions in non-overlapping bins of 500. Enrichments were calculated by dividing these fractions by the fraction of the genome in each respective term either in the bin or the 9,613 peaks. For binned plots, this was also done for the peak regions plus 50 kb.
Genomic distributions. The genomic annotation hg19 was downloaded from UCSC. Upstream was defined as 2 kb upstream of the first position of the first exon in a gene. Percentages were then calculated as described above for ChromHMM for all peaks.
STARR-seq centered heatmaps and average profile plots. The average coverage was calculated in 50bp non-overlapping windows for 40kb regions centered on STARR-seq peak summits using custom scripts in R and sorted by the total occupancy in a 2 kb window around the peak summit. Peaks were separated by the presence of DHS over input with a binomial P-value < 0.05 for heatmaps and meta plots. Heatmaps were made using Java TreeView version 1. 6.4 (ref. 57) . Average profile plots were constructed using the colMeans function in R.
STARR-seq distal versus proximal open peaks. Peaks were considered proximal (n = 951) if the peak edges were within 10kb of the nearest annotated transcript TSS. Distal intronic peaks (n = 460) were more than 50kb away from the nearest annotated TSS and had a summit overlapping an intron. Intergenic peaks (N = 954) were more than 50kb away from the nearest TSS and had a summit overlapping intergenic regions. All three categories required a DHS P-value < 0.001. For these 3 categories motif analysis was done over the 9613 random regions. The average coverage for ENCODE ChIP-seq data sets ( Supplementary Table 3 ) was calculated in 50bp non-overlapping windows for 10kb regions centered on STARR-seq peak summits using custom scripts in R. Average profile plots were constructed from coverage window averages using the colMeans function in R.
ENCODE RNA-seq processing. Fastq files were downloaded from the ENCODE RNA-seq dashboard. We only considered cell lines for which polyA-selected total RNA was paired-end sequenced in at least 2 replicates. Protein coding transcripts (Gencode release 23 (ref. 58)) were quantified using kallisto 0.43.0 (ref. 59) with sequence bias correction (−bias) and sample bootstrapping (-b 30). For each transcript, counts were normalized to sequencing depth (cpm), summarized to gene level and over replicates and then log 2 transformed using EdgeR's cpm function (prior.count = 2).
ENCODE RNA-seq based clustering. Log 2 transformed, genelevel counts were clustered using pheatmap 1.0.8 (ref. 60) (maximum distance matrix, complete linkage clustering).
Normalized enrichment scores from i-cisTarget. Normalized enrichment scores (NES) for DNase-seq and ChIPseq data sets were obtained from i-cisTarget 26 with default settings (minimum fraction of overlap of 0.4, ROC threshold of 0.005). We filtered all DHS data sets for ENCODE DNase-seq data sets only (NES cutoff > 3.5) and only considered HeLa-S3 ChIP-seq data sets (NES cutoff > 3.0). Only the maximum score for multiple scores from the same feature description was kept. The NES scores were visualized using pheatmap (v1.0.8 (ref. 60)).
Repeat enrichments. Peaks containing repeat elements were identified by coordinate intersection with the UCSC RepeatMasker track for release GRCh37 (ref. 33) using bedtools. (-a peak -b repeat -F 1.0, -f 0.1). Genomic background frequencies were calculated within 1x10 6 randomly sampled genomic regions with the same size and chromosomal distribution as STARR-seq input fragments. Odds ratios and P-values were calculated with a twosided Fisher's exact test using contingency tables of insertion frequencies. P-values were adjusted to FDRs using R's p.adjust.
Active versus inactive ERV elements. Active and inactive ERV elements were defined by intersection with STARR-seq peaks using bedtools intersect (-a peak -b repeat with option -F 1.0 -f 0.1). For i-cisTarget analysis, we repeatedly (n = 5) sampled 1,783 inactive elements and averaged NES scores from the individual subsamples. For motif analysis, all inactive elements were considered. An inactive ERV element was annotated as STAT containing if either STAT1, STAT1:STAT2, or STAT3 motifs were present within the element (N = 25,203). For each element in the three groups, H3K9me3 counts were calculated with bedtools coverage with options -counts -F 0.1 and then divided by the length multiplied by 10 6 and displayed in log 10 . For STARR-seq box plots, the average coverage was calculated in R and displayed as log 10 values. For both analyses, negative infinite values resulting from log 10 transforming were set to the minimal in each group (for plotting only). P-values were calculated with one-sided Wilcoxon-ranksum tests in R on non-transformed values.
Core promoter motifs in ORI. We searched for known core promoter motifs in the ORI using position-weight matrices (PWMs) for 5 selected core promoter motifs 61, 62 . PWMs for TATA-box, Initiator (INR), downstream promoter element (DPE) and E-box were obtained from Ohler et al. 62 and PWM for TCT motif from Parry et al. 63 . At every position along the ORI the sequence was scored against the respective PWM and the score was converted to the percentage of the maximal possible PWM score (perfect motif match). Strong motif matches (x≥90%) were visualized along the beginning of the ORI sequence around the main initiation sites within the ORI.
qPCR analysis for ISG expression. Ct values for each target gene were normalized to ACTB using the delta-Ct method 64 . Deltadelta-Ct values were calculated between electroporations with and without DNA and displayed in log 2 .
qPCR analysis for reporter assay. Firefly luciferase Ct values for each candidate enhancer were normalized to Renilla firefly Ct values using the delta-Ct method 64 . Delta-delta-Ct values were calculated between enhancer candidates and a negative control and displayed in log 2 . In the case of enhancer activity changes upon inhibitor treatment (Fig. 2f) , delta-delta-Ct values were calculated between electroporations with and without inhibitor treatment. Table 5 contains all P-values and details for t and Wilcoxon tests. We performed two replicates per NGS experiment, except if equivalent experiments independently confirmed the results.
Statistics and reproducibility. Supplementary
Code availability. Custom scripts for analysis are available upon request.
Data availability. All protocols are also available from Protocol Exchange [65] [66] [67] [68] . All files are available at http://starklab.org/data/ muerdter_boryn_2017/. All next-generation sequencing data is available at http://www.starklab.org/ and was deposited to GEO (GSE100432). All external data sets are listed in Supplementary  Table 3 . Plasmids are available from Addgene (IDs 99291-99324). Corresponding author(s): Alexander Stark
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Experimental design 1. Sample size
Describe how sample size was determined. For single-candidate luciferase assays, we performed experiments in triplicates (independent transfections), as is standard in the field. For NGS experiments, we performed two replicates, as is standard in the field, except if equivalent experiments independently confirmed the results.
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All replication attempts were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Not relevant because the samples were not grouped.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All experiments were done in cell culture and did not involve animal or human research participants and blinding did therefore not apply.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
